Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era
Year: 2023
Type: review
Abstract: The outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge on public health systems. Despite the measures put in place to contain it, COVID-19 is likely to continue experiencing sporadic outbreaks for some time, and individuals will remain susceptible to recurrent infections. Chimeric antigen receptor (CAR)-T recipients are characterized by durable B-cell aplasia, hypogammaglobulinemia and loss of T-cell diversity, which lead to an increased proportion of severe/critical cases and a high mortality rate after COVID-19 infection. Thus, treatment decisions have become much more complex and require greater caution when considering CAR T-cell immunotherapy. Hence, we reviewed the current understanding of COVID-19 and reported clinical experience in the management of COVID-19 and CAR-T therapy. After a panel discussion, we proposed a rational procedure pertaining to CAR-T recipients with the aim of maximizing the benefit of CAR-T therapy in the post COVID-19 pandemic era.
Authors: Tingting Zhang, Weiwei Tian, Shuang Wei, Xinyi Lu, Jing An, Shaolong He, Jie Zhao, Zhilin Gao, Li Li, Ke Lian, Qiang Zhou, Huilai Zhang, Liang Wang, Liping Su, Huicong Kang, Ting Niu, Ailin Zhao, Jing Pan, Qingqing Cai, Zhenshu Xu, Wenming Chen, Hongmei Jing, Peng Li, Wanhong Zhao, Yang Cao, Jianqing Mi, Tao Chen, Yuan Chen, Ping Zou, Veronika Lukacs-Kornek, Christian Kurts, Jian Li, Xiansheng Liu, Qi Mei, Yicheng Zhang, Jia Wei
Institutions: Shanxi Medical University, Shanxi Academy of Medical Sciences, Tongji Hospital, Huazhong University of Science and Technology, Tianjin Medical University Cancer Institute and Hospital, Beijing Tongren Hospital, Capital Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Shanxi Provincial Cancer Hospital, Sichuan University, West China Hospital of Sichuan University, Sun Yat-sen University Cancer Center, Fujian Medical University, Union Hospital, Beijing Chao-Yang Hospital, Capital Medical University, Peking University Third Hospital, Chinese Academy of Sciences, Guangzhou Institutes of Biomedicine and Health, Second Affiliated Hospital of Xi'an Jiaotong University, Shanghai Jiao Tong University, Ruijin Hospital, Shanghai Institute of Hematology, Wuhan Union Hospital, University of Bonn
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,990
OpenAlex ID: W4385303941